M

Microba Life Sciences Ltd
ASX:MAP

Watchlist Manager
Microba Life Sciences Ltd
ASX:MAP
Watchlist
Price: 0.071 AUD -1.39%
Market Cap: 43.2m AUD

Wall Street
Price Targets

MAP Price Targets Summary
Microba Life Sciences Ltd

Wall Street analysts forecast MAP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MAP is 0.219 AUD with a low forecast of 0.141 AUD and a high forecast of 0.305 AUD.

Lowest
Price Target
0.141 AUD
99% Upside
Average
Price Target
0.219 AUD
209% Upside
Highest
Price Target
0.305 AUD
329% Upside
Microba Life Sciences Ltd Competitors:
Price Targets
2522
Jiangxi Rimag Group Co Ltd
511% Upside
THYROCARE
Thyrocare Technologies Ltd
29% Upside
CCRN
Cross Country Healthcare Inc
46% Upside
MD
MEDNAX Inc
6% Upside
FLGT
Fulgent Genetics Inc
27% Upside
KRSNAA
Krsnaa Diagnostics Ltd
62% Upside
EUDA
EUDA Health Holdings Ltd
121% Upside
6197
Solasto Corp
35% Downside

Revenue
Forecast

Revenue Estimate
Microba Life Sciences Ltd

For the last 5 years the compound annual growth rate for Microba Life Sciences Ltd's revenue is 40%. The projected CAGR for the next 3 years is 26%.

40%
Past Growth
26%
Estimated Growth
Estimates Accuracy
0%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Microba Life Sciences Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
18%
Average Beat

Net Income
Forecast

Net Income Estimate
Microba Life Sciences Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MAP's stock price target?
Price Target
0.219 AUD

According to Wall Street analysts, the average 1-year price target for MAP is 0.219 AUD with a low forecast of 0.141 AUD and a high forecast of 0.305 AUD.

What is Microba Life Sciences Ltd's Revenue forecast?
Projected CAGR
26%

For the last 5 years the compound annual growth rate for Microba Life Sciences Ltd's revenue is 40%. The projected CAGR for the next 3 years is 26%.

Back to Top